4-碘-2,7-萘啶-1(2H)-酮 | 959558-50-0

• 物质功能分类: 化学试剂 - 有机试剂 - 多环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-碘-2,7-萘啶-1(2H)-酮
• 中文别名: 4-碘-1,2-二氢-2,7-萘啶-1-酮
• 英文名称: 4-iodo-2,7-naphthyridin-1(2H)-one
• 英文别名: 4-iodo-2H-[2,7]naphthyridin-1-one；4-iodo-2H-2,7-naphthyridin-1-one
• CAS: 959558-50-0
• 化学式: C₈H₅IN₂O
• 分子量: 272.045
• InChiKey: ZBDXNQRDQVRSPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-碘-2,7-萘啶-1(2H)-酮 在 盐酸 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 sodium hydride 、 联硼酸频那醇酯 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.92h， 生成 (2S,4S)-N-(2-((5-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide
  参考文献：
  名称：

  Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

  摘要：

  Developing PROTACs to redirect the ubiquitination activity of E3 ligases and potently degrade a target protein within cells can be a lengthy and unpredictable process, and it remains unclear whether any combination of E3 and target might be productive for degradation. We describe a probe-quality degrader for a ligase-target pair deemed unsuitable: the von Hippel-Lindau (VHL) and BRD9, a bromodomain-containing subunit of the SWI/SNF chromatin remodeling complex BAF. VHL-based degraders could be optimized from suboptimal compounds in two rounds by systematically varying conjugation patterns and linkers and monitoring cellular degradation activities, kinetic profiles, and ubiquitination, as well as ternary complex formation thermodynamics. The emerged structure-activity relationships guided the discovery of VZ185, a potent, fast, and selective degrader of BRD9 and of its close homolog BRD7. Our findings qualify a new chemical tool for BRD7/9 knockdown and provide a roadmap for PROTAC development against seemingly incompatible target-ligase combinations.

  DOI：

  10.1021/acs.jmedchem.8b01413
• 作为产物：
  描述：

  4-甲基烟酸甲酯 在 氨 、 碘 、 sodium hydroxide 作用下， 以 乙二醇二甲醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 39.0h， 生成 4-碘-2,7-萘啶-1(2H)-酮
  参考文献：
  名称：

  吡啶或哒嗪并环化合物及其应用

  摘要：

  本发明公开了吡啶或哒嗪并环化合物、其药学上可接受的盐及其溶剂化物。本发明也提供了该类化合物的制备方法、含有该类化合物的组合物以及该类化合物用于制备治疗与EED蛋白和/或PRC2蛋白复合物作用机理相关疾病或障碍的药物用途。

  公开号：

  CN110563722A

文献信息

• Novel Heterocyclic Compounds as Bromodomain Inhibitors
  申请人：Liu Shuang

  公开号：US20140179648A1

  公开（公告）日：2014-06-26

  The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

  本公开涉及一些化合物，这些化合物通过结合溴结构域对BET蛋白功能进行抑制，并且它们在治疗中的应用。
• [EN] 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER<br/>[FR] [1,8]-NAPHTYRIDINES SUBSTITUÉES PAR 2,4-DIARYLE EN TANT QU'INHIBITEURS DE KINASE, DESTINÉES À UNE UTILISATION CONTRE LE CANCER
  申请人：MERCK PATENT GMBH

  公开号：WO2012000595A1

  公开（公告）日：2012-01-05

  The present invention relates to novel [1,8]naphthyridine derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

  本发明涉及新型[1,8]萘啶衍生物的化学式(I)，以及利用这类化合物在ATP消耗蛋白质如激酶中抑制、调节和/或调制信号传导的用途，特别是TGF-beta受体激酶的抑制剂，以及利用这类化合物治疗激酶诱导的疾病，尤其是肿瘤的治疗。
• 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER
  申请人：Dorsch Dieter

  公开号：US20130102603A1

  公开（公告）日：2013-04-25

  The present invention relates to novel [1,8]naphthyridine derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

  本发明涉及公式（I）的新型[1,8]萘啶衍生物，以及利用这些化合物在ATP消耗蛋白质如激酶中发挥作用的信号传导的抑制、调节和/或调控，特别是TGF-beta受体激酶的抑制剂，以及利用这些化合物治疗激酶诱导疾病，特别是治疗肿瘤的用途。
• Preparation of Polyfunctional Naphthyridines by Cobalt-Catalyzed Cross-Couplings of Halogenated Naphthyridines with Magnesium and Zinc Organometallics
  作者：Robert Greiner、Dorothée S. Ziegler、Denise Cibu、Andreas C. Jakowetz、Florian Auras、Thomas Bein、Paul Knochel

  DOI：10.1021/acs.orglett.7b03242

  日期：2017.12.1

  CoCl2 (5%) catalyzes cross-couplings of various halogenated naphthyridines with alkyl- and arylmagnesium halides. Also, arylzinc halides undergo smooth cross-couplings with various naphthyridines in the presence of CoCl2·2LiCl (5%) and sodium formate (50%), leading to polyfunctional arylated naphthyridines. Two of these arylated naphthyridines are highly fluorescent, with quantum efficiencies reaching

  CoCl 2（5％）催化各种卤代萘啶与烷基和芳基镁卤化物的交叉偶联。另外，在CoCl 2 ·2LiCl（5％）和甲酸钠（50％）的存在下，芳基卤化锌与各种萘啶进行平滑的交叉偶联，从而得到多官能的芳基化萘啶。这些芳基化萘啶中的两个具有高荧光性，量子效率达到95％，激发态寿命长达12 ns。
• 7-AZAINDOLE DERIVATIVES
  申请人：Dorsch Dieter

  公开号：US20130310391A1

  公开（公告）日：2013-11-21

  Compounds of the formula (I) in which R, R 1 , R 2 and R 3 have the meanings indicated in Claim 1 , are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours.

  式（I）中R、R1、R2和R3的化合物具有在权利要求1中指示的含义，可以抑制PDK1和细胞增殖/细胞活力，并可用于肿瘤的治疗。